Aggarwal et al. Efgartigimod in myositis, phase 3 ALKIVIA RCT. Effective IMNM and DM in both Total Improvement Score and secondary outcomes. No new safety signals. @RheumNow#ACR26 Abstr#LB24
Kalunian et al. Phase 2 RCT of Afimetoran, oral TLR 7/8i in SLE. 248 patients. Met SRI-4 in all groups. No dose dependent effect. Less serious adverse events with afimetoran vs placebo. @RheumNow#ACR26 Abstr#LB23
Noaiseh et al. Phase 3 OASIZ-301 RCT. Dazodalibep in Sjogens. Positive study. Effect by week 4. Secondary outcomes on sicca also met. Similar adverse events to placebo. @RheumNow#ACR26 Abstr#LB22
Wang et al. Retrospective cohort study. Hypogammaglobulinaemia in RA with RTX. The more you give the worse it gets (slowly and steadily). Threshold of 600 mg/dl appears to be tipping point in infection risk, HR 6.25, 95% CI 2.54-15.39; p< 0.001. @RheumNow#ACR26 Abstr#2931
Riley et al. Mosaic loss of Y chromosome in men with RA. Present in 520/2157 (24%). In univariate model associated incident ILD, CV disease, mortality. Attenuated in multivariable models and (just) no longer statistically significant. ?Power issue @RheumNow#ACR26 Abstr#2930